Oxford Biomedica Inks Aura Biosciences Commercial Pact for Phase 3 Eye Drug
Oxford Biomedica confirmed a commercial manufacturing pact for Aura Biosciences' Phase 3 eye cancer drug bel-sar, securing Durham capacity ahead of PPQ runs.
Oxford Biomedica confirmed a commercial manufacturing agreement with Aura Biosciences on Tuesday morning, November 17, 2026, initiating technical transfer for Aura's late-stage eye cancer therapy bel-sar. For biotech investors, locking in commercial-scale production ahead of pivotal Phase 3 trial data mitigates a critical manufacturing and regulatory hurdle and provides Oxford Biomedica with steady, high-margin CDMO revenue.
What happened
Under the agreement announced in London on November 17, 2026, Oxford Biomedica will manufacture commercial supply of belzupacap sarotalocan (bel-sar), a first-in-class virus-like drug conjugate (VDC) targeting early-stage choroidal melanoma. Technical transfer has commenced to prepare for Process Performance Qualification (PPQ) at Oxford Biomedica’s FDA-approved, commercial-scale facility in Durham, North Carolina, backed by process development at its Bedford, Massachusetts site.
Following the material disclosure, Oxford Biomedica shares (LSE: OXB) traded steady around 528.00p in London, supporting a market capitalisation of roughly £643 million. Meanwhile, Aura Biosciences (NASDAQ: AURA) shares hovered near $7.11, having traded within a 52-week range of $4.73 to $9.52.
Why it matters
Manufacturing bottlenecks frequently derail oncology biotechs just as clinical trials cross the finish line. By establishing validated commercial supply and PPQ protocols during Phase 3, Aura actively mitigates chemistry, manufacturing, and controls (CMC) risks before approaching regulators. Bel-sar is currently undergoing the global Phase 3 CoMpass trial as a vision-sparing alternative to radioactive plaques and enucleation.
For Oxford Biomedica, the pact solidifies its strategic push beyond pure viral vectors into virus-like conjugates, broadening its economic moat across contract development and manufacturing. Commercial-stage CDMO contracts offer recurring multi-year cash flow that helps buffer the clinical trial volatility typical of pure-play biopharma equities.
What to watch next
- PPQ validation milestones: Progress on process qualification and validation batches at the Durham facility.
- Phase 3 CoMpass updates: Clinical trial progress and pivotal safety and tumor control readouts for bel-sar in choroidal melanoma.
- CDMO order book: Signs of revenue contributions and margin expansion in Oxford Biomedica's future financial statements.
Sources (2)
This analysis is for information only and is not investment advice. Prices and figures as of publication.